{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:36:10Z","timestamp":1789180570210,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.dmd.2025.100226","type":"journal-article","created":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T07:39:26Z","timestamp":1766475566000},"page":"100226","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir"],"prefix":"10.1016","volume":"54","author":[{"given":"Amit S.","family":"Kalgutkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2914-3967","authenticated-orcid":false,"given":"Heather","family":"Eng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa L.","family":"Dantonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3724-6517","authenticated-orcid":false,"given":"Eugene P.","family":"Kadar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6117-9022","authenticated-orcid":false,"given":"Li","family":"Di","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0129-1682","authenticated-orcid":false,"given":"Gregory S.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britton","family":"Boras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Scott","family":"Obach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.dmd.2025.100226_bib1","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.dmd.2025.100226_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.ajem.2020.03.036","article-title":"Coronavirus disease (COVID-19): a primer for emergency physicians","volume":"44","author":"Chavez","year":"2021","journal-title":"Am J Emerg Med"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib3","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","article-title":"Origin and evolution of pathogenic coronaviruses","volume":"17","author":"Cui","year":"2019","journal-title":"Nat Rev Microbiol"},{"issue":"10224","key":"10.1016\/j.dmd.2025.100226_bib5","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","article-title":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding","volume":"395","author":"Lu","year":"2020","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib6","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41579-020-00459-7","article-title":"Characteristics of SARS-COV-2 and COVID-19","volume":"19","author":"Hu","year":"2021","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"10.1016\/j.dmd.2025.100226_bib7","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/d41573-020-00151-8","article-title":"Evolution of the COVID-19 vaccine development landscape","volume":"19","author":"Le","year":"2020","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib8","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/vaccines10010062","article-title":"A narrative review of COVID-19 vaccines","volume":"10","author":"Eroglu","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-022-00996-y","article-title":"COVID-19 vaccine development: milestones, lessons and prospects","volume":"7","author":"Li","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"7824","key":"10.1016\/j.dmd.2025.100226_bib10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-020-2423-5","article-title":"Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2","volume":"585","author":"Williamson","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib11","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1038\/s41467-021-23328-0","article-title":"Drug repurposing screens identity chemical entities for the development of COVID-19 interventions","volume":"12","author":"Bakowski","year":"2021","journal-title":"Nat Commun"},{"issue":"628","key":"10.1016\/j.dmd.2025.100226_bib12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl7430","article-title":"A phase 2a clinical trial of molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus","volume":"14","author":"Fischer","year":"2022","journal-title":"Sci Transl Med"},{"issue":"6575","key":"10.1016\/j.dmd.2025.100226_bib13","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"issue":"6536","key":"10.1016\/j.dmd.2025.100226_bib14","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1126\/science.abf1611","article-title":"SARS-CoV-2 Mpro inhibitors with antiviral activity in a transgenic mouse model","volume":"371","author":"Qiao","year":"2021","journal-title":"Science"},{"issue":"9","key":"10.1016\/j.dmd.2025.100226_bib15","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a noncovalent oral SARS-CoV-2 3CL protease inhibitor clinical candidate for treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib16","doi-asserted-by":"crossref","first-page":"6463","DOI":"10.1038\/s41467-023-42102-y","article-title":"Structure-based development and preclinical evaluation of the SARS-CoV-2 3C-like protease inhibitor simnotrelvir","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.dmd.2025.100226_bib17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1177\/10915818221095489","article-title":"Comprehensive nonclinical safety assessment of nirmatrelvir supporting timely development of the SARS-COV-2 antiviral therapeutic, PaxlovidTM","volume":"41","author":"Sathish","year":"2022","journal-title":"Int J Toxicol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib18","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmd.2025.100226_bib19","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/cpt.2683","article-title":"Metabolism and excretion of nirmatrelvir in humans using quantitative fluorine nuclear magnetic resonance spectroscopy: a novel approach for accelerating drug development","volume":"112","author":"Singh","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.dmd.2025.100226_bib20","first-page":"2118","article-title":"FDA grants full approval to Paxlovid, COVID-19 antiviral treatment","volume":"329","author":"Harris","year":"2023","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.dmd.2025.100226_bib21","doi-asserted-by":"crossref","first-page":"6595","DOI":"10.1021\/acs.jmedchem.5b01461","article-title":"An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: peptidomimetics and small molecule chemotherapy","volume":"59","author":"Pillaiyar","year":"2016","journal-title":"J Med Chem"},{"issue":"7811","key":"10.1016\/j.dmd.2025.100226_bib22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"issue":"5626","key":"10.1016\/j.dmd.2025.100226_bib23","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1126\/science.1085658","article-title":"Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs","volume":"300","author":"Anand","year":"2003","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.dmd.2025.100226_bib24","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"10.1016\/j.dmd.2025.100226_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41589-020-00689-z","article-title":"SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging","volume":"17","author":"Rut","year":"2021","journal-title":"Nat Chem Biol"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1021\/acs.jmedchem.5b00825","article-title":"A journey around the medicinal chemistry of hepatitis C virus inhibitors targeting NS4B: from target to preclinical drug candidates","volume":"59","author":"Cannalire","year":"2016","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.dmd.2025.100226_bib27","doi-asserted-by":"crossref","first-page":"5172","DOI":"10.1021\/acs.jmedchem.5b01697","article-title":"Recent progress in the development of HIV-1 protease inhibitors for the treatment of HIV\/AIDS","volume":"59","author":"Ghosh","year":"2016","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.dmd.2025.100226_bib28","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of ketone-based covalent inhibitors of coronavirus 3CL proteases for the potential therapeutic treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib29","doi-asserted-by":"crossref","first-page":"6055","DOI":"10.1038\/s41467-021-26239-2","article-title":"Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19","volume":"12","author":"Boras","year":"2021","journal-title":"Nat Commun"},{"issue":"6489","key":"10.1016\/j.dmd.2025.100226_bib30","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.abb3405","article-title":"Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved \u03b1-ketoamide inhibitors","volume":"368","author":"Zhang","year":"2020","journal-title":"Science"},{"issue":"12","key":"10.1016\/j.dmd.2025.100226_bib31","doi-asserted-by":"crossref","first-page":"4639","DOI":"10.1021\/cr010182v","article-title":"Irreversible inhibitors of serine, cysteine, and threonine proteases","volume":"102","author":"Powers","year":"2002","journal-title":"Chem Rev"},{"issue":"12","key":"10.1016\/j.dmd.2025.100226_bib32","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.dmd.2025.100226_bib33","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1002\/jps.22674","article-title":"Development of a new permeability assay using low-efflux MDCKII cells","volume":"100","author":"Di","year":"2011","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.cbpa.2008.03.009","article-title":"Peptidomimetics, a synthetic tool of drug discovery","volume":"12","author":"Vagner","year":"2008","journal-title":"Curr Opin Chem Biol"},{"issue":"11","key":"10.1016\/j.dmd.2025.100226_bib35","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1039\/D0CS00102C","article-title":"Peptidomimetic toolbox for drug discovery","volume":"49","author":"Lenci","year":"2020","journal-title":"Chem Soc Rev"},{"issue":"18","key":"10.1016\/j.dmd.2025.100226_bib36","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.4155\/fmc-2020-0180","article-title":"Evidence supporting the use of peptides and peptidomimetics as potential SARS-CoV-2 (COVID-19) therapeutics","volume":"12","author":"VanPatten","year":"2020","journal-title":"Future Med Chem"},{"issue":"10","key":"10.1016\/j.dmd.2025.100226_bib37","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1124\/dmd.123.001416","article-title":"The metabolism of lufotrelvir, a prodrug investigated for the treatment of SARS-COV2 in humans following intravenous administration","volume":"51","author":"Cheruvu","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"10.1016\/j.dmd.2025.100226_bib38","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/nm1777","article-title":"Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs","volume":"14","author":"Shen","year":"2008","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.dmd.2025.100226_bib39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2893.2010.01314.x","article-title":"Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors","volume":"18","author":"Mo","year":"2011","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.dmd.2025.100226_bib40","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1128\/AAC.06283-11","article-title":"Pharmacokinetic\/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors","volume":"56","author":"Reddy","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.dmd.2025.100226_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1023\/A:1008629608556","article-title":"Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir","volume":"19","author":"Hoetelmans","year":"1997","journal-title":"Pharm World Sci"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib42","doi-asserted-by":"crossref","first-page":"158","DOI":"10.2174\/157488710792007293","article-title":"Recent advances in hepatitis C virus treatment: review of HCV protease inhibitor clinical trials","volume":"5","author":"Chary","year":"2010","journal-title":"Rev Recent Clin Trials"},{"issue":"12","key":"10.1016\/j.dmd.2025.100226_bib43","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1002\/jps.21756","article-title":"N-(3,4-dimethoxyphenethyl)-4-(6,7-dimethoxy-3,4-dihydroisoquinolin-2[1H]-yl)-6,7-dimethoxyquinazolin-2-amine (CP-100,356) as a \u201cchemical knock-out equivalent\u201d to assess the impact of efflux transporters on oral drug absorption in the rat","volume":"98","author":"Kalgutkar","year":"2009","journal-title":"J Pharm Sci"},{"issue":"7","key":"10.1016\/j.dmd.2025.100226_bib44","first-page":"e01819","article-title":"A comparative analysis of SARS-CoV-2 antivirals characterizes 3CLpro inhibitor PF-00835231 as a potential new treatment for COVID-19","volume":"95","author":"de Vries","year":"2021","journal-title":"J Virol"},{"issue":"5","key":"10.1016\/j.dmd.2025.100226_bib45","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/dmd.30.5.488","article-title":"Current progress on esterases: from molecular structure to function","volume":"30","author":"Satoh","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib46","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2133\/dmpk.21.173","article-title":"Human carboxylesterase isozymes: catalytic properties and rational drug design","volume":"21","author":"Imai","year":"2006","journal-title":"Drug Metab Pharmacokinet"},{"issue":"10","key":"10.1016\/j.dmd.2025.100226_bib47","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1021\/tx300243v","article-title":"Insights into the novel hydrolytic mechanism of a diethyl-2-phenyl-2-(2-arylacetoxy)methylmalonate ester-based microsomal triglyceride transfer protein (MTP) inhibitor","volume":"25","author":"Ryder","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"8","key":"10.1016\/j.dmd.2025.100226_bib48","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.3390\/molecules27082561","article-title":"Covalent reversible inhibitors of cysteine proteases containing the nitrile warhead: recent advancement in the field of viral and parasitic diseases","volume":"27","author":"Brogi","year":"2022","journal-title":"Molecules"},{"issue":"6","key":"10.1016\/j.dmd.2025.100226_bib49","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1021\/jm0303857","article-title":"In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1\u2019 subsite and its implications to structure-based drug design","volume":"48","author":"Costanzo","year":"2005","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.dmd.2025.100226_bib50","doi-asserted-by":"crossref","first-page":"3508","DOI":"10.1021\/acs.jmedchem.0c01808","article-title":"The alpha keto amide moiety as a privileged motif in medicinal chemistry: current insights and emerging opportunities","volume":"64","author":"Robello","year":"2021","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.dmd.2025.100226_bib51","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1124\/dmd.121.000801","article-title":"Disposition of nirmatrelvir, an orally bioavailable inhibitor of SARS-CoV-2 3C-like protease, across animals and humans","volume":"50","author":"Eng","year":"2022","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2025.100226_bib52","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/psp4.12466","article-title":"The importance of the human mass balance study in regulatory submissions","volume":"8","author":"Coppola","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib53","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1021\/tx2005629","article-title":"Alternate strategies to obtain mass balance without the use of radiolabeled compounds: application of quantitative fluorine (19F) nuclear magnetic resonance (NMR) spectroscopy in metabolism studies","volume":"25","author":"Mutlib","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"4","key":"10.1016\/j.dmd.2025.100226_bib54","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1124\/dmd.116.073809","article-title":"Comparison between radioanalysis and 19F nuclear magnetic resonance spectroscopy in the determination of mass balance, metabolism, and distribution of pefloxacin","volume":"45","author":"Hu","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100226_bib55","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1124\/dmd.117.075424","article-title":"Comparison of 19F NMR and 14C measurements for the assessment of ADME of BYL719 (alpelisib) in humans","volume":"45","author":"James","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.dmd.2025.100226_bib56","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/00498254.2018.1523488","article-title":"19F-NMR-based determination of the absorption, metabolism and excretion of the oral phosphatidylinositol-3-kinase (PI3K) delta inhibitor leniolisib (CDZ173) in healthy volunteers","volume":"49","author":"Pearson","year":"2019","journal-title":"Xenobiotica"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib57","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/03602530600952172","article-title":"What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs","volume":"39","author":"Roffey","year":"2007","journal-title":"Drug Metab Rev"},{"issue":"8","key":"10.1016\/j.dmd.2025.100226_bib58","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s11095-023-03538-5","article-title":"Physiologically-based pharmacokinetic modeling of PAXLOVIDTM with first-order absorption kinetics","volume":"40","author":"Sagawa","year":"2023","journal-title":"Pharm Res"},{"issue":"1","key":"10.1016\/j.dmd.2025.100226_bib59","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.xphs.2023.09.028","article-title":"PBPK modeling of PAXLOVIDTM incorporating rotamer conversion kinetics to advanced dissolution and absorption model","volume":"113","author":"Jaini","year":"2024","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.dmd.2025.100226_bib60","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1021\/acscentsci.3c00145","article-title":"Development of the commercial manufacturing process for nirmatrelvir in 17 months","volume":"9","author":"Allais","year":"2023","journal-title":"ACS Cent Sci"},{"issue":"11","key":"10.1016\/j.dmd.2025.100226_bib61","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","article-title":"Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics","volume":"87","author":"Wacher","year":"1998","journal-title":"J Pharm Sci"},{"issue":"10","key":"10.1016\/j.dmd.2025.100226_bib62","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.3390\/curroncol31100450","article-title":"Ritonavir\u2019s evolving role: a journey from antiretroviral therapy to broader medical applications","volume":"31","author":"Pereira","year":"2024","journal-title":"Curr Oncol"},{"issue":"15","key":"10.1016\/j.dmd.2025.100226_bib63","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19","volume":"386","author":"Hammond","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.dmd.2025.100226_bib64","doi-asserted-by":"crossref","first-page":"13550","DOI":"10.1021\/acs.jmedchem.3c02469","article-title":"A second-generation oral SARS-CoV-2 main protease inhibitor clinical candidate for the treatment of COVID-19","volume":"67","author":"Allerton","year":"2024","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.dmd.2025.100226_bib65","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/cid\/ciae529","article-title":"Virologic response and safety of ibuzatrelvir, a novel SARS-CoV-2 antiviral, in adults with COVID-19","volume":"80","author":"Mortezavi","year":"2025","journal-title":"Clin Infect Dis"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955625095352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T10:21:49Z","timestamp":1771928509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955625095352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0090955625095352"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100226","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absorption, distribution, metabolism, and excretion tactics toward the expedited discovery and development of the severe acute respiratory syndrome coronavirus-2 main protease inhibitor nirmatrelvir","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2025.100226","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 American Society for Pharmacology and Experimental Therapeutics. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100226"}}